ClinicalTrials.gg
Active, not recruitingNCT05074810RAMP203Updated Jan 12, 2026

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients

A Phase 1/2 interventional study of avutometinib and sotorasib and avutometinib and sotorasib and defactinib in Non Small Cell Lung Cancer and KRAS Activating Mutation, sponsored by Verastem, Inc.. Active, not recruiting at 35 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Verastem, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 10 under way, 1 of them phase 3. sotorasib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
2nd of 19
153 · median 24
Started
2022
with 8 others
Phase 1/2
4 of 19
1 open now
Registered
5th of 19
by date

Among the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, this one is the 2nd largest by planned enrollment, is one of 9 that started in 2022, is one of 4 in phase 1/2, and was the 5th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About sotorasib

sotorasib: first FDA approval 2021 (LUMAKRAS), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing sotorasib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.

Read the detailed description

This is a multicenter, non-randomized, open-label Phase 1/2 study designed to evaluate safety and tolerability and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C mutant NSCLC.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • KRAS Activating Mutation

Keywords

  • NSCLC
  • KRAS G12C
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥ 18 years of age
  • Histologic or cytologic evidence of NSCLC
  • Known KRAS G12C mutation
  • Either exposed or not exposed to a KRAS inhibitor to be included in Part A (avutometinib + sotorasib + defactinib) and not exposed to KRAS inhibitor to be included in Part B (avutometinib + sotorasib + defactinib), Cohort 1
  • Received at least 1 dose of a G12C inhibitor to be included in Part B, Cohort 2 (avutometinib + sotorasib + defactinib)
  • Must have received appropriate treatment with at least one prior systemic regimen, but no more than 2 prior regimens, for Stage 3B-C or 4 NSCLC
  • according to 1.1
  • An Eastern Cooperative Group () performance status ≤ 1
  • Adequate organ function
  • Adequate recovery from toxicities related to prior treatments
  • Agreement to use highly effective method of

Exclusion criteria

Exclusion Criteria:

  • Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy
  • History of prior , with the exception of curatively treated malignancies
  • Major surgery within 4 weeks, minor surgery within 2 weeks (excluding placement of vascular access)
  • History of treatment with a direct and specific inhibitor of MEK
  • Exposure to strong inhibitors or inducers within 14 days prior to the first dose and during the course of therapy
  • Symptomatic requiring or other local interventions.
  • Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy
  • Known , , or infection that is active
  • Active skin disorder that has required systemic therapy within the past year
  • History of rhabdomyolysis
  • Concurrent ocular disorders
  • Concurrent heart disease or severe obstructive pulmonary disease
  • Inability to swallow oral medications
  • Female patients that are pregnant or breastfeeding
  • Previously treated with sotorasib and were dose reduced due to toxicity
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    avutometinib (VS-6766)+sotorasib

    To determine the recommended phase 2 dose (RP2D) for avutometinib (VS 6766) in combination with sotorasib in KRAS G12C inhibitor naïve and exposed patients

    Drug: avutometinib and sotorasib

  • Experimental
    avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor naïve

    To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients

    Drug: avutometinib and sotorasib

  • Experimental
    avutometinib (VS-6766)+sotorasib - KRAS G12C inhibitor exposed

    To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients

    Drug: avutometinib and sotorasib

  • Experimental
    avutometinib (VS-6766)+sotorasib+defactinib

    To determine the recommended phase 2 dose (RP2D) for avutometinib (VS-6766) in combination with sotorasib and defactinib in KRAS G12C inhibitor exposed patients

    Drug: avutometinib and sotorasib and defactinib

  • Experimental
    avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor naive

    To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor naïve patients

    Drug: avutometinib and sotorasib and defactinib

  • Experimental
    avutometinib (VS-6766)+sotorasib+defactinib - KRAS G12C inhibitor exposed

    To determine the efficacy of the RP2D identified from Part A in KRAS G12C inhibitor exposed patients

    Drug: avutometinib and sotorasib and defactinib

Interventions

  • Drugavutometinib and sotorasib

    Drug pages: RO5126766 · Sotorasib

    The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion

    Also known as: AMG 510, LUMAKRAS™, VS-6766

  • Drugavutometinib and sotorasib and defactinib

    Drug pages: RO5126766 · Sotorasib · Defactinib

    The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion

    Also known as: AMG 510, LUMAKRAS™, VS-6766, VS-6063

06

What researchers measure

Primary outcomes

  1. Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib

    Assessment of Dose-limiting toxicities (DLTs)

    Time frame: From start of treatment to confirmation of RP2D; 28 days

  2. Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part A

    Confirmed overall response rate per RECIST 1.1

    Time frame: From start of treatment to confirmation of response; 16 weeks

Secondary outcomes

  1. Frequency and severity adverse events (AEs) and Serious Adverse Events (SAEs)

    Count of AE and SAEs by grade, based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grading scale

    Time frame: 24 months

  2. Duration of Response (DOR)

    Time of first response to PD as assessed per RECIST 1.1

    Time frame: Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months

  3. Disease Control Rate (DCR)

    CR and PR stable disease as assessed per RECIST 1.1

    Time frame: Greater than or equal to 8 weeks

  4. Progression Free Survival (PFS)

    From the time of first dose of study intervention to PD or death from any cause

    Time frame: 24 months

  5. Overall Survival (OS)

    From time of first dose of study intervention to death

    Time frame: Up to 5 years

  6. Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites - Tmax

    time of Maximum concentration (Tmax)

    Time frame: 10 weeks

  7. Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites -AUC

    Area under plasma Concentration (AUC) 0 to t

    Time frame: 10 weeks

  8. Plasma Pharmacokinetics (PK) of avutometinib, sotorasib, defactinib and relevant metabolites half-life

    concentration Half-life (T1/2)

    Time frame: 10 weeks

07

Study locations

35 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Jun 2026, 50 months after the start.

Of 309 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 50 months is below that.

Counting every sponsor, half of 432 studies reached it within 63 months; a quarter within 42 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2021
First posted
Oct 12, 2021
StartActual
Apr 12, 2022
Primary completionEst.
Jun 2026
CompletionEst.
Apr 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05074810
Lead sponsor
Verastem, Inc.
Collaborators
Amgen
Responsible party
Sponsor
First posted
Oct 12, 2021
Start date
Apr 12, 2022
Primary completion
Jun 2026 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

MD Verastem
study director · Verastem, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: RO5126766 · Sotorasib · Defactinib

Start the discussion